EHC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Encompass Health Corp (EHC) is currently not a strong buy for a beginner investor with a long-term strategy. While the company has strong financial performance and positive recognition in the industry, the lack of significant trading signals, insider selling, and neutral technical indicators suggest waiting for a better entry point.
The MACD is positive but contracting, RSI is neutral at 55.674, and moving averages are converging, indicating no strong trend. The stock is trading below the pivot point of 108.945, with support at 104.563 and resistance at 113.326.
The company has been recognized on the Fortune 2026 World's Most Admired Companies and Forbes' 2026 America's Best Companies lists. Financial performance is strong, with revenue up 9.94% YoY, net income up 21.65% YoY, and EPS up 21.19% YoY in Q4 2025.
Insider selling has increased significantly by 13423.86% over the last month. Hedge funds are neutral, and there are no significant trading trends. Technical indicators are neutral, and no strong trading signals are present.
In Q4 2025, revenue increased to $1.5446 billion (up 9.94% YoY), net income rose to $146.1 million (up 21.65% YoY), EPS grew to $1.43 (up 21.19% YoY), and gross margin improved slightly to 90.23%.
Barclays raised the price target to $153 from $150 and maintains an Overweight rating, reflecting optimism in the stock's long-term potential.
